Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease
Sponsor: Novartis Pharmaceuticals
Summary
The study is a phase II trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 in pediatric and adult participants with Still's disease
Official title: An Open-label Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease
Key Details
Gender
All
Age Range
1 Year - 100 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2025-11-03
Completion Date
2029-05-24
Last Updated
2026-03-30
Healthy Volunteers
No
Conditions
Interventions
MAS825
Experimental drug
Locations (22)
Cincinnati Childrens Hospital
Cincinnati, Ohio, United States
Legacy Emanuel Research Hosp Portland
Portland, Oregon, United States
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Bordeaux, France
Novartis Investigative Site
Bron, France
Novartis Investigative Site
Le Kremlin-Bicêtre, France
Novartis Investigative Site
Lille, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Sankt Augustin, North Rhine-Westphalia, Germany
Novartis Investigative Site
Heidelberg, Germany
Novartis Investigative Site
Münster, Germany
Novartis Investigative Site
Florence, FI, Italy
Novartis Investigative Site
Genova, GE, Italy
Novartis Investigative Site
Roma, RM, Italy
Novartis Investigative Site
Utrecht, Netherlands
Novartis Investigative Site
Esplugues, Barcelona, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Valencia, Spain
Novartis Investigative Site
Istanbul, Fatih, Turkey (Türkiye)
Novartis Investigative Site
Ankara, Sihhiye-Altindag, Turkey (Türkiye)